Jason Liu

Jason Liu

Auto-generated profile, based on publicly available information

Jason Liu

Computational Biology and Bioinformatics Program, Yale University, New Haven, Connecticut 06511, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Science
Verified
Journal Article
Closed access
PEPrashant S Emani
Prashant S Emani
JLJason J Liu
Jason J Liu
DCDeclan Clarke
Declan Clarke
MJMatthew Jensen
Matthew Jensen
JWJonathan Warrell
Jonathan Warrell
PCPsychENCODE Consortium
PsychENCODE Consortium
Single-cell genomics is a powerful tool for studying heterogeneous tissues such as the brain. Yet little is understood about how genetic variants influence cell-level gene expression. Addressing this, we uniformly processed single-nuclei, multiomics datasets into a resource comprising >2.8 million nuclei from the prefrontal cortex across 388 individuals. For 28 cell types, we assessed population-level variation in expression and chromatin across gene families and drug targets. We identified >550,000 cell type–specific regulatory elements and >1.4 million single-cell expression quantitative trait loci, which we used to build cell-type regulatory and cell-to-cell communication networks. These networks manifest cellular changes in aging and neuropsychiatric disorders. We further constructed an integrative model accurately imputing single-cell expression and simulating perturbations; the model prioritized ~250 disease-risk genes and drug targets with associated cell types.

25 June 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
DLDonghoon Lee
Donghoon Lee
JZJing Zhang
Jing Zhang
JLJason Liu
Jason Liu
MGMark Gerstein
Mark Gerstein
Alternative RNA splicing provides an important means to expand metazoan transcriptome diversity. Contrary to what was accepted previously, splicing is now thought to predominantly take place during transcription. Motivated by emerging data showing the physical proximity of the spliceosome to Pol II, we surveyed the effect of epigenetic context on co-transcriptional splicing. In particular, we observed that splicing factors were not necessarily enriched at exon junctions and that most epigenetic signatures had a distinctly asymmetric profile around known splice sites. Given this, we tried to build an interpretable model that mimics the physical layout of splicing regulation where the chromatin context progressively changes as the Pol II moves along the guide DNA. We used a recurrent-neural-network architecture to predict the inclusion of a spliced exon based on adjacent epigenetic signals, and we showed that distinct spatio-temporal features of these signals were key determinants of model outcome, in addition to the actual nucleotide sequence of the guide DNA strand. After the model had been trained and tested (with >80% precision-recall curve metric), we explored the derived weights of the latent factors, finding they highlight the importance of the asymmetric time-direction of chromatin context during transcription. In humans, only about 2% of the genome is comprised of so-called coding regions and can give rise to protein products. However, the human transcriptome is much more diverse than the number of genes found in these coding regions. Each gene can give rise to multiple transcripts through a process during transcription called alternative splicing. There is a limited understanding of the regulation of splicing and the underlying splicing code that determines cell-type-specific splicing. Here, we studied epigenetic features that characterize splicing regulation in humans using a recurrent neural network model. Unlike feedforward neural networks, this method contains an internal memory state that learns from spatiotemporal patterns–like the context in language–from a sequence of genomic and epigenetic information, making it better suited for characterizing splicing. We demonstrated that our method improves the prediction of spicing outcomes compared to previous methods. Furthermore, we applied our method to 49 cell types in ENCODE to investigate splicing regulation and found that not only spatial but also temporal epigenomic context can influence splicing regulation during transcription.

21 July 2023 in Science Advances
Verified
Journal Article
Open access
CMChristopher J. Minteer
Christopher J. Minteer
KTKyra Thrush
Kyra Thrush
JGJohn Gonzalez
John Gonzalez
PNPeter Niimi
Peter Niimi
MRMariya Rozenblit
Mariya Rozenblit
MLMorgan E. Levine
Morgan E. Levine
Aging is a leading risk factor for cancer. While it is proposed that age-related accumulation of somatic mutations drives this relationship, it is likely not the full story. We show that aging and cancer share a common epigenetic replication signature, which we modeled using DNA methylation from extensively passaged immortalized human cells in vitro and tested on clinical tissues. This signature, termed CellDRIFT, increased with age across multiple tissues, distinguished tumor from normal tissue, was escalated in normal breast tissue from cancer patients, and was transiently reset upon reprogramming. In addition, within-person tissue differences were correlated with predicted lifetime tissue-specific stem cell divisions and tissue-specific cancer risk. Our findings suggest that age-related replication may drive epigenetic changes in cells and could push them toward a more tumorigenic state.

23 August 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
JLJason Liu
Jason Liu
DSDan Spakowicz
Dan Spakowicz
GAGarrett Ash
Garrett Ash
RHRebecca Hoyd
Rebecca Hoyd
RARohan Ahluwalia
Rohan Ahluwalia
MGMark Gerstein
Mark Gerstein
The development of mobile-health technology has the potential to revolutionize personalized medicine. Biomedical sensors (e.g., wearables) can assist with determining treatment plans for individuals, provide quantitative information to healthcare providers, and give objective measurements of health, leading to the goal of precise phenotypic correlates for genotypes. Even though treatments and interventions are becoming more specific and datasets more abundant, measuring the causal impact of health interventions requires careful considerations of complex covariate structures, as well as knowledge of the temporal and spatial properties of the data. Thus, interpreting biomedical sensor data needs to make use of specialized statistical models. Here, we show how the Bayesian structural time series framework, widely used in economics, can be applied to these data. This framework corrects for covariates to provide accurate assessments of the significance of interventions. Furthermore, it allows for a time-dependent confidence interval of impact, which is useful for considering individualized assessments of intervention efficacy. We provide a customized biomedical adaptor tool, MhealthCI, around a specific implementation of the Bayesian structural time series framework that uniformly processes, prepares, and registers diverse biomedical data. We apply the software implementation of MhealthCI to a structured set of examples in biomedicine to showcase the ability of the framework to evaluate interventions with varying levels of data richness and covariate complexity and also compare the performance to other models. Specifically, we show how the framework is able to evaluate an exercise intervention’s effect on stabilizing blood glucose in a diabetes dataset. We also provide a future-anticipating illustration from a behavioral dataset showcasing how the framework integrates complex spatial covariates. Overall, we show the robustness of the Bayesian structural time series framework when applied to biomedical sensor data, highlighting its increasing value for current and future datasets.

11 July 2025 in Genome Research
Verified
Journal Article
Open access
PDF file
SGSophia C. Gaynor-Gillett
Sophia C. Gaynor-Gillett
LCLijun Cheng
Lijun Cheng
MSManman Shi
Manman Shi
JLJason Liu
Jason Liu
GWGaoyuan Wang
Gaoyuan Wang
KWKevin P. White
Kevin P. White
Genome-wide association studies (GWASs) and expression analyses implicate noncoding regulatory regions as harboring risk factors for psychiatric disease, but functional characterization of these regions remains limited. Here, we perform capture STARR-sequencing of over 70,000 candidate regions to identify active enhancers in primary human neural progenitor cells (phNPCs). We select candidate regions by integrating data from NPCs, prefrontal cortex, developmental timepoints, and GWASs. Over 8000 regions demonstrate enhancer activity in the phNPCs, and we link these regions to over 2200 predicted target genes. These genes are involved in neuronal and psychiatric disease-associated pathways, including neuronal system, nervous system development, and developmental delay. We functionally validate a subset of these enhancers using mutation STARR-sequencing and CRISPR deletions, demonstrating the effects of genetic variation on enhancer activity and enhancer deletion on gene expression. Overall, we identify thousands of highly active enhancers and functionally validated a subset of these enhancers, improving our understanding of regulatory networks underlying brain function and disease.

30 August 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
SLShaoke Lou
Shaoke Lou
KCKellie A Cotter
Kellie A Cotter
TLTianxiao Li
Tianxiao Li
JLJin Liang
Jin Liang
HMHussein Mohsen
Hussein Mohsen
MGMark Gerstein
Mark Gerstein
There has been much effort to prioritize genomic variants with respect to their impact on “function”. However, function is often not precisely defined: sometimes it is the disease association of a variant; on other occasions, it reflects a molecular effect on transcription or epigenetics. Here, we coupled multiple genomic predictors to build GRAM, a GeneRAlized Model, to predict a well-defined experimental target: the expression-modulating effect of a non-coding variant on its associated gene, in a transferable, cell-specific manner. Firstly, we performed feature engineering: using LASSO, a regularized linear model, we found transcription factor (TF) binding most predictive, especially for TFs that are hubs in the regulatory network; in contrast, evolutionary conservation, a popular feature in many other variant-impact predictors, has almost no contribution. Moreover, TF binding inferred from in vitro SELEX is as effective as that from in vivo ChIP-Seq. Second, we implemented GRAM integrating only SELEX features and expression profiles; thus, the program combines a universal regulatory score with an easily obtainable modifier reflecting the particular cell type. We benchmarked GRAM on large-scale MPRA datasets, achieving AUROC scores of 0.72 in GM12878 and 0.66 in a multi-cell line dataset. We then evaluated the performance of GRAM on targeted regions using luciferase assays in the MCF7 and K562 cell lines. We noted that changing the insertion position of the construct relative to the reporter gene gave very different results, highlighting the importance of carefully defining the exact prediction target of the model. Finally, we illustrated the utility of GRAM in fine-mapping causal variants and developed a practical software pipeline to carry this out. In particular, we demonstrated in specific examples how the pipeline could pinpoint variants that directly modulate gene expression within a larger linkage-disequilibrium block associated with a phenotype of interest (e.g., for an eQTL). With advances in sequencing technologies, a deluge of genomic data is available; however, only a fraction of non-coding genomic variants are functionally relevant. Sifting through this data to prioritize genomic variants with respect to function is an important but challenging task. In this study, we built GRAM, a GeneRAlized Model, to predict the expression-modulating effects of non-coding variants in a cell-specific manner. GRAM combines a universal regulatory score defined by transcription factor binding with an easily obtainable modifier defined by transcription factor binding and expression to reflect the particular cell type. We evaluated this framework on multiple cell lines with high performance and showed that it could be applied to any cell line or sample with gene expression data. We also integrated GRAM into a practical software pipeline to fine-map causal variants that directly modulate gene expression among a larger linkage-disequilibrium block associated with a phenotype of interest. GRAM complements other general variant effect prediction methods–which often combine disparate features–by helping to precisely define the subset of prioritized variants that directly alters gene expression.